Generali Investments CEE investicni spolecnost a.s. Purchases Shares of 3,000 IQVIA Holdings Inc. $IQV

Generali Investments CEE investicni spolecnost a.s. acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 3,000 shares of the medical research company’s stock, valued at approximately $570,000.

A number of other hedge funds also recently made changes to their positions in IQV. Asset Dedication LLC raised its stake in IQVIA by 224.0% during the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after acquiring an additional 168 shares during the period. Trust Co. of Toledo NA OH purchased a new stake in shares of IQVIA in the second quarter worth $39,000. J.Safra Asset Management Corp raised its position in shares of IQVIA by 208.6% during the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 169 shares during the period. Rothschild Investment LLC lifted its stake in shares of IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after buying an additional 124 shares in the last quarter. Finally, NewSquare Capital LLC increased its stake in IQVIA by 185.3% in the 2nd quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock worth $46,000 after buying an additional 189 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 1.7%

Shares of NYSE:IQV opened at $224.44 on Tuesday. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $234.29. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The firm has a market capitalization of $38.22 billion, a PE ratio of 30.79, a price-to-earnings-growth ratio of 2.47 and a beta of 1.37. The business has a 50 day simple moving average of $219.47 and a two-hundred day simple moving average of $193.38.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on IQV. HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. Stifel Nicolaus upped their target price on shares of IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Baird R W raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 29th. Citigroup upped their price objective on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a report on Wednesday, October 29th. Finally, Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $243.19.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.